Ipsen’s statements and announcements

Key highlights

Ipsen and Medetia join forces to accelerate early research in rare disease

– 06 June 2023 – 0 mins read

06 June 2023 – 0 mins read

Ipsen and Medetia join forces to accelerate early research in rare disease

Filter

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 5 Media Statements

Show

Sort

Ipsen announces sale of Priority Review Voucher for $158m

– 27 August 2024

27 August 2024

Ipsen announces sale of Priority Review Voucher for $158m

PARIS, FRANCE, 27 August 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) has entered into an agreement to sell its rare pediatric disease Priority Review Voucher (PRV) to a large global pharmaceutical company. Ipsen received the PRV coinciding with the SohonosTM…

Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation

– 22 June 2023

22 June 2023

Ipsen CEO David Loew is elected to EFPIA leadership; joins industry partners to warn of impact of EU pharma legislation

– 06 June 2023

06 June 2023

Ipsen and Medetia join forces to accelerate early research in rare disease

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

– 24 April 2023

24 April 2023

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Ipsen is committed to bringing innovative medicines to the rare disease community where a significant unmet need exists and innovation in treatments is lacking.

Offering support to those impacted in Turkey & Syria

– 20 February 2023

20 February 2023

Offering support to those impacted in Turkey & Syria

We are deeply saddened by the tragic earthquake across Turkey and Syria and the worsening humanitarian crisis. Our thoughts are with all of those impacted by the devastating events and our gratitude to those who are bravely leading the rescue…